State Street’s Aegerion Pharmaceuticals AEGR Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2016
Q4 | – | Sell |
-40,719
| Closed | -$121K | – | 3717 |
|
|
2016
Q3 | $121K | Sell |
40,719
-500
| -1% | -$867 | ﹤0.01% | 3437 |
|
|
2016
Q2 | $60K | Sell |
41,219
-393,716
| -91% | -$901K | ﹤0.01% | 3578 |
|
|
2016
Q1 | $1.6M | Buy |
434,935
+11,077
| +3% | +$68.6K | ﹤0.01% | 3074 |
|
|
2015
Q4 | $4.28M | Buy |
+423,858
| New | +$5.1M | ﹤0.01% | 2614 |
|
|
2015
Q2 | – | Sell |
-1,264,946
| Closed | -$33.1M | – | 3806 |
|
|
2015
Q1 | $33.1M | Sell |
1,264,946
-22,542
| -2% | -$574K | ﹤0.01% | 1479 |
|
|
2014
Q4 | $27M | Buy |
1,287,488
+321,508
| +33% | +$8.1M | ﹤0.01% | 1580 |
|
|
2014
Q3 | $32.2M | Sell |
965,980
-27,378
| -3% | -$850K | ﹤0.01% | 1406 |
|
|
2014
Q2 | $31.9M | Buy |
993,358
+81,180
| +9% | +$3.02M | ﹤0.01% | 1480 |
|
|
2014
Q1 | $42.1M | Buy |
912,178
+113,811
| +14% | +$6.67M | ﹤0.01% | 1300 |
|
|
2013
Q4 | $56.6M | Buy |
798,367
+18,191
| +2% | +$1.39M | 0.01% | 1129 |
|
|
2013
Q3 | $66.9M | Buy |
780,176
+18,937
| +2% | +$1.61M | 0.01% | 1002 |
|
|
2013
Q2 | $48.2M | Buy |
+761,239
| New | +$40.4M | 0.01% | 1135 |
|
State Street's AEGR Position: Q4 2016 in Review
State Street sold out of Aegerion Pharmaceuticals (AEGR) in Q4 2016, closing a stake of 40,719 shares — an estimated $121K sold.
State Street first reported a position in AEGR in Q2 2013 and held it in 12 quarters. The position peaked at $66.9M in Q3 2013. 0 funds tracked by Wall St. Rank hold AEGR as of Q4 2016.
- State Street reported no remaining Aegerion Pharmaceuticals position as of Q4 2016 after selling out during the quarter.
- State Street sold 40,719 Aegerion Pharmaceuticals shares in Q4 2016, an estimated $121K.
- State Street first reported a position in Aegerion Pharmaceuticals in Q2 2013 and held it in 12 quarters.
- State Street's Aegerion Pharmaceuticals position peaked at $66.9M in Q3 2013.
- 0 funds tracked by Wall St. Rank held Aegerion Pharmaceuticals as of Q4 2016.
Based on State Street's 13F filing for Q4 2016, filed 9 Feb 2017.